Published: 11 April 2019
Analyst(s): Finance Research Team
Learn the optimal cost structure for earning excess shareholder returns in the pharmaceuticals, biotechnology and life sciences industry. CFOs should use this information to inform board-level discussions about cost structure in a highly cyclical revenue growth and margin environment.
The Cost Structure Challenge
Guidance on Benchmarking Your Total Cost Structure
Trends in Pharmaceuticals, Biotechnology and Life Sciences Industry Growth and Profitability
Growth Strategies and Cost Structure in the Pharmaceuticals, Biotechnology and Life Sciences Industry
Operating Costs in the Pharmaceuticals, Biotechnology and Life Sciences Industry
Invested Capital in the Pharmaceuticals, Biotechnology and Life Sciences Industry
Operating Working Capital
Net Intangible Assets
About This Research
©2022 Gartner, Inc. and/or its affiliates.
All rights reserved.
Gartner is a registered trademark of Gartner, Inc. and its affiliates.
This publication may not be reproduced or distributed in any form without Gartner’s prior written permission.
It consists of the opinions of Gartner’s research organization, which should not be construed as statements of fact.
While the information contained in this publication has been obtained from sources believed to be reliable, Gartner disclaims all warranties as to the accuracy, completeness or adequacy of such information.
Although Gartner research may address legal and financial issues, Gartner does not provide legal or investment advice and its research should not be construed or used as such.
Your access and use of this publication are governed by Gartner’s Usage Policy.
Gartner prides itself on its reputation for independence and objectivity.
Its research is produced independently by its research organization without input or influence from any third party.
For further information, see
Guiding Principles on Independence and Objectivity.